MCID: CYS014
MIFTS: 51

Cystadenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Cystadenocarcinoma

MalaCards integrated aliases for Cystadenocarcinoma:

Name: Cystadenocarcinoma 12 54 43 15 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:3111
MeSH 43 D003536
NCIt 49 C2971
SNOMED-CT 67 21008007
UMLS 71 C0010631

Summaries for Cystadenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, in which cystic accumulations of retained secretions are formed.

MalaCards based summary : Cystadenocarcinoma is related to bile duct cystadenocarcinoma and mucinous cystadenocarcinoma. An important gene associated with Cystadenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and Innate Immune System. The drugs Lenograstim and Irinotecan have been mentioned in the context of this disorder. Affiliated tissues include pancreas, ovary and breast, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Cystadenocarcinoma is a malignant form of a cystadenoma and is a cancer derived from glandular... more...

Related Diseases for Cystadenocarcinoma

Diseases related to Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 623)
# Related Disease Score Top Affiliating Genes
1 bile duct cystadenocarcinoma 34.5 MUC1 KRT7 CEACAM5
2 mucinous cystadenocarcinoma 34.2 VIM MUC2 MUC16 MUC1 KRT7 CEACAM5
3 ovarian cystadenocarcinoma 33.9 ZNF217 TP53 PIK3CA MUC16 MUC1 HRAS
4 appendix adenocarcinoma 33.3 KRT7 HRAS CEACAM5
5 serous cystadenocarcinoma 33.2 ZNF217 VEGFA TP53 PPP2R1A PIK3CA PGR
6 ovarian serous cystadenocarcinoma 32.5 ZNF217 VEGFA TP53 PPP2R1A PIK3CA PGR
7 papillary serous adenocarcinoma 32.4 TP53 PGR KRT7 CEACAM5
8 cystadenoma 31.7 PGR MUC16 MUC1 KRT7 CEACAM5 CEACAM3
9 cystic teratoma 31.2 TP53 MUC16 KRT7 CEACAM5
10 adenoma 31.2 TP53 PIK3CA MUC1 KRT7 BRAF
11 intrahepatic cholangiocarcinoma 31.2 TP53 MUC1 KRT7 ERBB2
12 teratoma 31.2 VIM TP53 KRT7 CEACAM5 AKT1
13 pseudomyxoma peritonei 31.1 TP53 MUC2 MUC16 MUC1 KRT7 CEACAM5
14 krukenberg carcinoma 31.1 MUC1 KRT7 CEACAM5
15 ovarian cystadenoma 30.9 MUC16 KRT7 CEACAM5
16 ovarian mucinous neoplasm 30.9 KRT7 HRAS CEACAM5
17 benign teratoma 30.9 NANOG KRT7 CEACAM5
18 polymorphous low-grade adenocarcinoma 30.8 VIM MUC1 CEACAM3
19 spindle cell sarcoma 30.8 VIM VEGFA MUC1 KRT7
20 papillary carcinoma 30.8 PGR MUC1 KRT7 ERBB2 BRAF
21 appendiceal neoplasm 30.8 KRT7 CEACAM5
22 villous adenoma 30.7 MUC1 HRAS CEACAM5 BRAF
23 urachal adenocarcinoma 30.7 CEACAM5 BRAF
24 small cell carcinoma 30.7 TP53 MUC1 KRT7
25 rhabdoid tumor predisposition syndrome 1 30.7 VIM TP53 MUC1
26 mucinous adenocarcinoma 30.6 VIM VEGFA TP53 PGR MUC16 MUC1
27 in situ carcinoma 30.6 TP53 PGR MUC1 HRAS ERBB2 AKT1
28 angiosarcoma 30.6 VIM VEGFA TP53 MUC1 KRT7
29 mucoepidermoid carcinoma 30.6 TP53 MUC2 MUC1 KRT7 ERBB2 CEACAM5
30 lymphangioma 30.6 VIM VEGFA PIK3CA
31 ovarian carcinosarcoma 30.6 TP53 PPP2R1A PIK3CA ERBB2
32 papillary adenocarcinoma 30.6 VIM TP53 PGR MUC16 MUC1 KRT7
33 cavernous hemangioma 30.6 VIM VEGFA MUC1 KRT7
34 pleomorphic adenoma 30.6 VIM TP53 MUC1 KRT7 HRAS ERBB2
35 breast fibroadenoma 30.6 TP53 PGR ERBB2
36 polycystic liver disease 1 with or without kidney cysts 30.6 MUC16 MUC1 KRT7 CEACAM5 CEACAM3
37 appendix cancer 30.6 TP53 MUC1 KRT7 HRAS CEACAM5
38 myoma 30.6 PGR MUC16 CEACAM5
39 mature teratoma 30.6 TP53 NANOG KRT7 ERBB2 CEACAM5 BRAF
40 sclerosing hemangioma 30.5 PGR MUC1 KRT7
41 collecting duct carcinoma 30.5 VIM MUC1 KRT7
42 adenocarcinoma 30.5 VEGFA TP53 PIK3CA MUC1 KRT7 HRAS
43 papillary adenoma 30.5 VIM TP53 KRT7 HRAS
44 endosalpingiosis 30.5 TP53 PGR MUC1 KRT7
45 testicular germ cell tumor 30.5 TP53 HRAS AKT1
46 hemangioma 30.5 VEGFA TP53 PGR MUC1 KRT7 AKT1
47 colon adenocarcinoma 30.5 VEGFA TP53 PIK3CA ERBB2 CEACAM5
48 endodermal sinus tumor 30.5 VIM NANOG MUC16
49 mucinous ovarian cystadenoma 30.5 KRT7 CEACAM5
50 small cell cancer of the lung 30.5 TP53 PIK3CA KRT7 CEACAM5

Graphical network of the top 20 diseases related to Cystadenocarcinoma:



Diseases related to Cystadenocarcinoma

Symptoms & Phenotypes for Cystadenocarcinoma

GenomeRNAi Phenotypes related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.89 BRAF HRAS MUC1 PIK3CA
2 Decreased viability GR00221-A-1 9.89 HRAS PIK3CA
3 Decreased viability GR00221-A-2 9.89 HRAS PIK3CA
4 Decreased viability GR00221-A-3 9.89 HRAS
5 Decreased viability GR00221-A-4 9.89 BRAF PIK3CA
6 Decreased viability GR00301-A 9.89 BRAF
7 Decreased viability GR00381-A-1 9.89 BRAF
8 Decreased viability GR00402-S-2 9.89 BRAF HRAS MUC1 PIK3CA
9 Decreased cell migration GR00055-A-1 9.73 AKT1 BRAF HRAS MUC1 PIK3CA VIM
10 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.63 ERBB2 HRAS MUC1 PPP2R1A VEGFA VIM
11 Increased cell death HMECs cells GR00103-A-0 9.1 FBXW7 PGR PIK3CA PPP2R1A TP53 ZNF217

MGI Mouse Phenotypes related to Cystadenocarcinoma:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 AKT1 B2M BRAF ERBB2 FBXW7 KRT7
2 cardiovascular system MP:0005385 10.29 AKT1 B2M BRAF ERBB2 FBXW7 HRAS
3 homeostasis/metabolism MP:0005376 10.25 AKT1 B2M BRAF ERBB2 FBXW7 HRAS
4 embryo MP:0005380 10.2 AKT1 B2M BRAF ERBB2 FBXW7 NANOG
5 endocrine/exocrine gland MP:0005379 10.17 AKT1 B2M BRAF ERBB2 FBXW7 HRAS
6 mortality/aging MP:0010768 10.17 AKT1 B2M BRAF ERBB2 FBXW7 HRAS
7 digestive/alimentary MP:0005381 10.08 B2M BRAF ERBB2 FBXW7 HRAS MUC2
8 integument MP:0010771 10.07 AKT1 B2M BRAF ERBB2 FBXW7 HRAS
9 neoplasm MP:0002006 9.93 AKT1 B2M BRAF ERBB2 FBXW7 HRAS
10 muscle MP:0005369 9.86 AKT1 BRAF ERBB2 PGR PIK3CA TP53
11 normal MP:0002873 9.61 AKT1 BRAF ERBB2 FBXW7 HRAS PGR
12 respiratory system MP:0005388 9.23 AKT1 BRAF ERBB2 FBXW7 HRAS TP53

Drugs & Therapeutics for Cystadenocarcinoma

Drugs for Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 226)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3 135968-09-1
2
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
3
Pembrolizumab Approved Phase 3 1374853-91-4
4
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
5
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
6
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
7
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 5284616 6436030 46835353
8
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
9
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
10
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177 70789204
11
leucovorin Approved Phase 3 58-05-9 6006 143
12
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
13
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
14
Fluorouracil Approved Phase 3 51-21-8 3385
15
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
16
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
17
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
18
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
19
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
20
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
21
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
22
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
23
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
24
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
25
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
26
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
27
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
28
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
29
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
30
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
31
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
32 Edrecolomab Experimental, Investigational Phase 3 156586-89-9
33
Camptothecin Experimental Phase 3 7689-03-4
34
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
35
Maleic acid Experimental, Investigational Phase 2, Phase 3 110-17-8, 110-16-7 444972
36 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
37 Adjuvants, Immunologic Phase 3
38 Tetrahydrofolates Phase 3
39 Formyltetrahydrofolates Phase 3
40 topoisomerase I inhibitors Phase 2, Phase 3
41 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3
42 Carotenoids Phase 3
43 Antimetabolites Phase 3
44 Estrogens Phase 2, Phase 3
45 Aromatase Inhibitors Phase 2, Phase 3
46 Hormone Antagonists Phase 2, Phase 3
47 Antifungal Agents Phase 2, Phase 3
48 Immunosuppressive Agents Phase 3
49 Steroid Synthesis Inhibitors Phase 2, Phase 3
50 Estrogen Receptor Antagonists Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 206)
# Name Status NCT ID Phase Drugs
1 A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA Completed NCT00002568 Phase 3 cisplatin;paclitaxel
2 A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma Completed NCT00003644 Phase 3 carboplatin;paclitaxel
3 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
4 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
5 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
6 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
7 A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
8 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
9 Phase III Randomized Study of Adjuvant Immunotherapy With Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for State II (Modified Astler-Coller B2) Adenocarcinoma of the Colon Completed NCT00002968 Phase 3
10 Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
11 Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
12 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Recruiting NCT03422198 Phase 3
13 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Recruiting NCT04095364 Phase 3 Carboplatin;Letrozole;Paclitaxel
14 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Recruiting NCT00719303 Phase 3
15 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Recruiting NCT03914612 Phase 3 Carboplatin;Paclitaxel
16 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
17 CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
18 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
19 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
20 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
21 A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
22 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
23 A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen;Tamoxifen Citrate;Topotecan;Topotecan Hydrochloride;Trametinib;Trametinib Dimethyl Sulfoxide
24 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
25 A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
26 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
27 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
28 Randomized Phase II/III Trial to Assess the Efficacy of Platinum-based Chemotherapy vs Standard Non-platinum Therapy in Patients With Platinum-resistant Recurrent Ovarian Cancer (ROC) Not yet recruiting NCT04055038 Phase 2, Phase 3 Platinum-Based Drug;Conventional chemotherapy
29 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
30 A Phase II/III Trial of Chemotherapy Alone Versus Chemotherapy Plus SCH 58500 in Newly Diagnosed Stage III Ovarian and Primary Peritoneal Cancer Patients With Greater Than or Equal to 0.5 cm and Less Than or Equal to 2 cm Residual Disease Following Surgery Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
31 A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO PRIMARY THERAPY Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
32 A Randomized, Double-Blinded, Placebo Controlled Phase III Trial Using Acetyl-L-Carnitine(ALC)(NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Withdrawn NCT01492920 Phase 3
33 A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas Unknown status NCT02283658 Phase 2 Everolimus;Letrozole
34 A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
35 A Phase II Study of TLK 286 in Platinum Resistant Advanced Epithelial Ovarian Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
36 LAPAROSCOPIC STAGING IN PATIENTS WITH INCOMPLETELY STAGED CANCERS OF THE OVARY Completed NCT00002538 Phase 2
37 A Phase II Evaluation of Belinostat (NSC #726630) and Carboplatin (NSC #241240) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00993616 Phase 2 belinostat;carboplatin
38 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
39 A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Suboptimally Debulked Stage III or IV Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
40 Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
41 Phase II Evaluation Of Neoadjuvant Chemotherapy, Interval Debulking Followed By Intraperitoneal Chemotherapy In Women With Stage III And IV Epithelial Ovarian Cancer, Fallopian Tube Cancer Or Primary Peritoneal Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
42 A Phase I-II Study of OSI-774 (Tarceva, Erlotinib) With Docetaxel/Carboplatin Followed by Maintenance Therapy With Tarceva as Treatment for Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
43 A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxane™) as Chemoimmunotherapy for Platinum-Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
44 A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00939809 Phase 2
45 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
46 A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT00888173 Phase 2 Brivanib Alaninate
47 A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01642082 Phase 2
48 A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma Completed NCT00025467 Phase 2 thalidomide
49 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
50 A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC# 683864,) in Combination With Carboplatin and Paclitaxel Followed by Temsirolimus Consolidation as First-Line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus

Search NIH Clinical Center for Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma

Genetic Tests for Cystadenocarcinoma

Anatomical Context for Cystadenocarcinoma

MalaCards organs/tissues related to Cystadenocarcinoma:

40
Pancreas, Ovary, Breast, Liver, Appendix, Salivary Gland, Colon

Publications for Cystadenocarcinoma

Articles related to Cystadenocarcinoma:

(show top 50) (show all 2244)
# Title Authors PMID Year
1
Role of cystic fluid in diagnosis of the pancreatic cystadenoma and cystadenocarcinoma. 54 61
18251127 2007
2
Improved early diagnosis of cystadenocarcinoma of the pancreas. 54 61
17287173 2007
3
Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. 54 61
10573510 1999
4
Immunohistochemical demonstration of nonspecific cross-reacting antigen in normal and neoplastic human tissues using a monoclonal antibody. Comparison with carcinoembryonic antigen localization. 54 61
2187320 1990
5
Measurement of CA125, carcinoembryonic antigen, and alpha-fetoprotein in ovarian cyst fluid: diagnostic adjunct to cytology. 54 61
1696873 1990
6
Cystadenocarcinoma of the pancreas: neo-adjuvant therapy and CEA monitoring. 54 61
2296199 1990
7
Histopathological evaluation of minor salivary gland papillary-cystic tumours: focus on genetic alterations in sialadenoma papilliferum and intraductal papillary mucinous neoplasm. 61
31505033 2020
8
18F-FDG PET/CT Findings in a Patient With Primary Mucinous Cystadenocarcinoma of the Breast. 61
31876834 2020
9
Humeral air sac cystadenocarcinoma in a rainbow lorikeet (Trichoglossus moluccanus). 61
32017026 2020
10
Low-grade Apocrine Intraductal Carcinoma: Expanding the Morphologic and Molecular Spectrum of an Enigmatic Salivary Gland Tumor. 61
31989433 2020
11
[Spectrum analysis of pathological classification in 463 cases with nasal and paranasal sinuses malignant tumors]. 61
31914269 2019
12
Identification of hub genes and key pathways associated with the progression of gynecological cancer. 61
31788113 2019
13
A Novel Scoring System for Pivotal Autophagy-Related Genes Predicts Outcomes after Chemotherapy in Advanced Ovarian Cancer Patients. 61
31533939 2019
14
Interpretable deep neural network for cancer survival analysis by integrating genomic and clinical data. 61
31865908 2019
15
Metastatic mucinous cystadenocarcinoma of the pancreas presenting as intractable back pain. 61
31791983 2019
16
Proceedings of the 2019 National Toxicology Program Satellite Symposium. 61
31645210 2019
17
Surgery for cystic tumors of pancreas: Report of high-volume, multicenter Indian experience over a decade. 61
31543321 2019
18
CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress. 61
31766991 2019
19
The androgen receptor expression and association with patient's survival in different cancers. 61
31759122 2019
20
Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA. 61
31607216 2019
21
A comprehensive understanding of ovarian carcinoma survival prognosis by novel biomarkers. 61
31646556 2019
22
NCOA4-RET and TRIM27-RET Are Characteristic Gene Fusions in Salivary Intraductal Carcinoma, Including Invasive and Metastatic Tumors: Is "Intraductal" Correct? 61
31162284 2019
23
Laparoscopic right colectomy associated with hyperthermic intraperitoneal chemotherapy as treatment for mucinous cystadenocarcinoma of the appendix - a video vignette. 61
31309644 2019
24
Identification of a 3-mRNA signature as a novel potential prognostic biomarker in patients with ovarian serous cystadenocarcinoma in G2 and G3. 61
31579405 2019
25
Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study. 61
31491988 2019
26
Etiologic Distribution of Pancreatic Cystic Lesions Identified on Computed Tomography/Magnetic Resonance Imaging. 61
31404022 2019
27
Mucinous cystadenocarcinoma in the renal pelvis: primary or secondary? Case report and literature review. 61
31084406 2019
28
Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome. 61
31406154 2019
29
Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer. 61
31399054 2019
30
Giant ovarian cystadenocarcinoma in an adult patient, a rare finding in modern times. 61
31308929 2019
31
Clinicopathological profile of adnexal masses presenting to a tertiary-care hospital in Bhutan. 61
31489290 2019
32
Characterisation of DOG-1 Expression in Salivary Gland Tumours and Comparison with Myoepithelial Markers. 61
29671211 2019
33
miR-340-FHL2 axis inhibits cell growth and metastasis in ovarian cancer. 61
31068580 2019
34
The rare entity of cystadenocarcinoma (CAC) in parotid gland: A single-center experience. 61
30857928 2019
35
A 35 Year Old Bangladeshi Lady with Hereditary Mucinous Ovarian Cancer, Complicated with Omental Metastasis. 61
31086172 2019
36
MiR-182-5p inhibited proliferation and migration of ovarian cancer cells by targeting BNIP3. 61
31081079 2019
37
Laparoscopy-assisted extended right hepatectomy for giant hemorrhagic hepatic cyst mimicking biliary cystadenocarcinoma: a case report. 61
30977012 2019
38
[Primary mucinous cystadenocarcinoma of breast: report of a case]. 61
30955277 2019
39
TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database. 61
30542790 2019
40
MRI Findings of Borderline Retroperitoneal Serous Cystadenocarcinoma. 61
30823957 2019
41
High-grade Features of Papillary Cystadenocarcinoma of the Parotid Gland. 61
30918612 2019
42
Sudden, Unexpected Death Due to Pseudo-Meigs Syndrome: A Case Report and Review of the Literature. 61
30359338 2019
43
Surgical management of a giant hepatic cyst with suspicious radiological features. 61
30482032 2019
44
Mucinous Cystadenoma of the Urachus and Review of Current Classification of Urachal Mucinous Cystic Neoplasms. 61
30398914 2019
45
Integrative Analysis of CD133 mRNA in Human Cancers Based on Data Mining. 61
30430389 2019
46
[Laparoscopic appendectomy for mucinous cystadenoma of the appendix]. 61
31120449 2019
47
Concomitant adenosquamous carcinoma and cystadenocarcinoma of the extrahepatic bile duct: A case report. 61
30705898 2019
48
Histo-epidemiological aspects of gynecological and breast cancers at the University Teaching Hospital of Yaoundé. 61
31558929 2019
49
Rare Breast Malignancy Subtypes: A Cytological, Histological, and Immunohistochemical Correlation. 61
31007516 2019
50
Elevated OGN expression correlates with the EMT signature and poor prognosis in ovarian carcinoma. 61
31933863 2019

Variations for Cystadenocarcinoma

Expression for Cystadenocarcinoma

Search GEO for disease gene expression data for Cystadenocarcinoma.

Pathways for Cystadenocarcinoma

Pathways related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 VIM VEGFA TP53 PPP2R1A MUC1 HRAS
2
Show member pathways
13.75 VIM VEGFA TP53 PPP2R1A PIK3CA NANOG
3
Show member pathways
13.72 PPP2R1A PIK3CA MUC2 MUC16 MUC1 HRAS
4
Show member pathways
13.61 VEGFA TP53 PPP2R1A PIK3CA HRAS ERBB2
5
Show member pathways
13.56 VEGFA PPP2R1A PIK3CA NANOG KRT7 HRAS
6
Show member pathways
13.53 TP53 PPP2R1A PIK3CA HRAS FBXW7 ERBB2
7
Show member pathways
13.38 VEGFA TP53 PPP2R1A PIK3CA HRAS CEACAM5
8
Show member pathways
13.32 VIM VEGFA PPP2R1A NANOG HRAS ERBB2
9
Show member pathways
13.18 TP53 PPP2R1A PIK3CA HRAS BRAF AKT1
10
Show member pathways
13.04 VIM VEGFA TP53 PPP2R1A PIK3CA NANOG
11
Show member pathways
13.02 VEGFA TP53 PPP2R1A PIK3CA HRAS ERBB2
12
Show member pathways
13.01 VEGFA TP53 PIK3CA HRAS B2M AKT1
13
Show member pathways
12.98 VEGFA PIK3CA HRAS ERBB2 BRAF AKT1
14
Show member pathways
12.97 VEGFA PIK3CA HRAS ERBB2 BRAF AKT1
15
Show member pathways
12.88 VEGFA TP53 PIK3CA HRAS ERBB2 BRAF
16 12.85 VEGFA TP53 PIK3CA HRAS ERBB2 BRAF
17 12.82 VEGFA TP53 HRAS ERBB2 BRAF AKT1
18
Show member pathways
12.81 VEGFA PIK3CA HRAS BRAF AKT1
19
Show member pathways
12.77 TP53 PPP2R1A PIK3CA HRAS ERBB2 AKT1
20
Show member pathways
12.75 VEGFA PIK3CA PGR HRAS AKT1
21
Show member pathways
12.75 TP53 PIK3CA HRAS ERBB2 BRAF AKT1
22
Show member pathways
12.74 TP53 PPP2R1A HRAS BRAF AKT1
23
Show member pathways
12.7 TP53 PIK3CA HRAS ERBB2 BRAF AKT1
24
Show member pathways
12.67 TP53 PIK3CA HRAS ERBB2 AKT1
25
Show member pathways
12.67 TP53 PIK3CA PGR MUC2 HRAS ERBB2
26
Show member pathways
12.58 VEGFA TP53 PIK3CA HRAS ERBB2 BRAF
27 12.55 VIM VEGFA TP53 PIK3CA HRAS ERBB2
28
Show member pathways
12.52 TP53 PIK3CA HRAS ERBB2 AKT1
29
Show member pathways
12.5 TP53 PPP2R1A PIK3CA HRAS AKT1
30
Show member pathways
12.49 TP53 PIK3CA HRAS ERBB2 BRAF AKT1
31
Show member pathways
12.47 PIK3CA HRAS BRAF AKT1
32
Show member pathways
12.46 VEGFA PIK3CA HRAS BRAF AKT1
33
Show member pathways
12.45 TP53 PIK3CA HRAS AKT1
34
Show member pathways
12.41 TP53 PIK3CA MUC1 HRAS ERBB2 BRAF
35
Show member pathways
12.4 PPP2R1A PIK3CA PGR BRAF AKT1
36
Show member pathways
12.39 PIK3CA HRAS ERBB2 AKT1
37 12.38 TP53 PIK3CA HRAS B2M AKT1
38
Show member pathways
12.36 PIK3CA HRAS ERBB2 AKT1
39
Show member pathways
12.35 PPP2R1A PIK3CA HRAS BRAF
40
Show member pathways
12.3 PIK3CA HRAS CEACAM5 CEACAM3
41 12.27 VEGFA TP53 BRAF AKT1
42 12.26 HRAS ERBB2 BRAF AKT1
43 12.25 TP53 PIK3CA HRAS AKT1
44 12.23 VEGFA TP53 BRAF AKT1
45
Show member pathways
12.22 TP53 HRAS BRAF AKT1
46
Show member pathways
12.22 TP53 PIK3CA HRAS AKT1
47
Show member pathways
12.22 VEGFA TP53 HRAS BRAF AKT1
48
Show member pathways
12.22 TP53 PIK3CA HRAS ERBB2 BRAF AKT1
49
Show member pathways
12.21 PIK3CA HRAS ERBB2 AKT1
50
Show member pathways
12.2 TP53 PIK3CA HRAS BRAF AKT1

GO Terms for Cystadenocarcinoma

Cellular components related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.44 VIM PPP2R1A PIK3CA MUC2 MUC16 MUC1

Biological processes related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.73 VEGFA HRAS ERBB2 AKT1
2 positive regulation of epithelial cell proliferation GO:0050679 9.69 VEGFA HRAS ERBB2
3 positive regulation of MAP kinase activity GO:0043406 9.67 VEGFA HRAS ERBB2
4 O-glycan processing GO:0016266 9.65 MUC2 MUC16 MUC1
5 negative regulation of gene expression GO:0010629 9.63 VEGFA TP53 PGR HRAS FBXW7 AKT1
6 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.62 MUC2 MUC16 MUC1 HRAS
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.56 VEGFA PIK3CA BRAF AKT1
8 phosphatidylinositol 3-kinase signaling GO:0014065 9.54 PIK3CA ERBB2 AKT1
9 anoikis GO:0043276 9.52 PIK3CA AKT1
10 positive regulation of gene expression GO:0010628 9.5 VIM VEGFA TP53 HRAS ERBB2 BRAF
11 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.46 TP53 MUC1
12 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.4 VEGFA TP53
13 cytokine-mediated signaling pathway GO:0019221 9.17 VIM VEGFA TP53 PIK3CA NANOG MUC1

Molecular functions related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 ZNF217 VIM VEGFA TP53 PPP2R1A PIK3CA
2 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.55 ZNF217 TP53 PGR NANOG MUC1
3 identical protein binding GO:0042802 9.32 VIM VEGFA TP53 PGR FBXW7 ERBB2

Sources for Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....